Latest Coya Therapeutics News & Updates

See the latest news and media coverage for Coya Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Coya Therapeutics

Clinical-stage biotechnology company developing regulatory T-cell therapies

coyatherapeutics.com

Headquarters: Houston, United States
Founded year: 2020
Company type: Private company
Number of employees: 10–18
Industry: Pharmaceuticals

Last updated October 14

Latest news about Coya Therapeutics

In short: Coya Therapeutics completed ALSTARS enrollment, launched an extension, and delayed its FTD trial.

Company announcements

September 8 Coya Therapeutics

Coya Therapeutics publishes preclinical results for COYA 303

The study combines IL-2 and a GLP-1 agonist to treat neurodegenerative diseases like ALS, FTD, and Alzheimer's.

September 1 Coya Therapeutics

Coya Therapeutics updates investors on pipeline progress and partnerships

COYA 302 ALS data expected Q1 2027; Dr. Reddy's partnership provides funding; cash runway extends to H2 2027.

August 11 Coya Therapeutics

Coya Therapeutics reports second quarter 2026 financial results

The company highlighted COYA 302 progress, including FDA Fast Track designation, and reported $43.2 million cash, enough to fund operations into 2027.

June 26 Coya Therapeutics

Coya Therapeutics CEO discusses FDA Fast Track for COYA 302

The interview covers the ALSTARS Phase 2 trial in ALS and plans for FTD expansion.

Media coverage

October 14 StreetInsider

Coya plans open-label extension of ALS trial, delays FTD study

Coya Therapeutics (NASDAQ: COYA) announced plans to initiate an open-label extension (OLE) of its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of...

October 5 Zone Bourse

Coya Therapeutics, Inc. completes full enrollment of the phase 2/3 ALSTARS trial on COYA 302 in the treatment of amyotrophic lateral sclerosis

Coya Therapeutics, Inc. announced the complete enrollment of the planned 120 participants in its phase 2/3 ALSTARS trial, evaluating COYA 302, the exclusive combination...

September 23 ALS News Today

Coya 302: A New Approach to Neurodegeneration

Coya has received IND (Investigational New Drug) approval to test Coya 302 in FTD. This trial will apply the same Treg-restoration science to a different...

August 11 Yahoo Finance

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

Never miss news about Coya Therapeutics

Track Coya Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Coya Therapeutics competitors & trending companies

Browse news for competitors to Coya Therapeutics and other trending companies.